Sampson, John H.

Challenges to curing primary brain tumours

Aldape, K., Brindle, K. M., Chesler, L., Chopra, R., Gajjar, A., Gilbert, M. R., Gottardo, N., Gutmann, D. H., Hargrave, D., Holland, E. C., et al. (2019) · Nature Reviews Clinical Oncology

Glioma Diagnosis and TreatmentBrain Metastases and Treatment

Cited by 959

Phase II Trial of Gefitinib in Recurrent Glioblastoma

Rich, J. N., Reardon, D. A., Peery, T., Dowell, J. M., Quinn, J. A., Penne, K. L., Wikstrand, C. J., Van Duyn, L. B., Dancey, J. E., McLendon, R. E., et al. (2004) · Journal of Clinical Oncology

Glioma Diagnosis and TreatmentLung Cancer Treatments and Mutations

Cited by 734

Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143

Omuro, A., Vlahovic, G., Lim, M., Sahebjam, S., Baehring, J., Cloughesy, T., Voloschin, A., Ramkissoon, S. H., Ligon, K. L., Latek, R., et al. (2018) · Neuro-Oncology

Cancer Immunotherapy and BiomarkersGlioma Diagnosis and Treatment

Cited by 486

OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143

Reardon, D. A., Omuro, A., Brandes, A. A., Rieger, J., Wick, A., Sepulveda, J., Phuphanich, S., de Souza, P., Ahluwalia, M. S., Lim, M., et al. (2017) · Neuro-Oncology

Glioma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 325

Direct Intracerebral Delivery of Cintredekin Besudotox (IL13-PE38QQR) in Recurrent Malignant Glioma: A Report by the Cintredekin Besudotox Intraparenchymal Study Group

Kunwar, S., Prados, M. D., Chang, S. M., Berger, M. S., Lang, F. F., Piepmeier, J. M., Sampson, J. H., Ram, Z., Gutin, P. H., Gibbons, R. D., et al. (2007) · Journal of Clinical Oncology

Glioma Diagnosis and TreatmentToxin Mechanisms and Immunotoxins

Cited by 325

Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma

Sayour, E. J., McLendon, P., McLendon, R., De Leon, G., Reynolds, R., Kresak, J., Sampson, J. H., & Mitchell, D. A. (2015) · Cancer Immunology, Immunotherapy

Glioma Diagnosis and TreatmentT-cell and B-cell Immunology

Cited by 196

Oncolytic virus-derived type I interferon restricts CAR T cell therapy

Evgin, L., Huff, A. L., Wongthida, P., Thompson, J., Kottke, T., Tonne, J., Schuelke, M., Ayasoufi, K., Driscoll, C. B., Shim, K. G., et al. (2020) · Nature Communications

CAR-T cell therapy researchVirus-based gene therapy research

Cited by 128

Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles

Sayour, E. J., De Leon, G., Pham, C., Grippin, A., Kemeny, H., Chua, J., Huang, J., Sampson, J. H., Sanchez-Perez, L., Flores, C., et al. (2017) · OncoImmunology

Immunotherapy and Immune ResponsesRNA Interference and Gene Delivery

Cited by 93

A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498.

Sampson, J. H., Omuro, A. M. P., Preusser, M., Lim, M., Butowski, N. A., Cloughesy, T. F., Strauss, L. C., Latek, R. R., Paliwal, P., Weller, M., et al. (2016) · Journal of Clinical Oncology

Glioma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 53